Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Mordor Intelligence | PRODUCT CODE: 1404357

Cover Image

PUBLISHER: Mordor Intelligence | PRODUCT CODE: 1404357

North America Novel Drug Delivery Systems (NDDS) - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2024 - 2029

PUBLISHED:
PAGES: 90 Pages
DELIVERY TIME: 2-3 business days
SELECT AN OPTION
PDF (Single User License)
USD 4750
PDF (Team License: Up to 7 Users)
USD 5250
PDF (Site License)
USD 6500
PDF (Corporate License)
USD 8750

Add to Cart

North America Novel Drug Delivery Systems (NDDS) - Market - IMG1

The major factors for the growth of the market include the growing need of controlled release of drugs, and technological advancements promoting the development of NDDS. Most of the drugs have an optimum concentration range and requirement of controlled release of drugs in the body. Concentrations above or below the prescribed range can be toxic or can produce no therapeutic benefits. Transdermal patches, nasal systems, microcapsules, etc., are some of the common systems that are considered under the controlled release systems. Hence, the requirement of the controlled release of drugs drives the novel drug delivery systems market. The stability of a delivery system is one of the most important factors that affect the drug delivery systems market. The restraining factors include stringent regulatory guidelines and product recalls.

North America Novel Drug Delivery Systems (NDDS) Market Trends

Oral Drug Delivery Systems is Expected to Grow Fastest during the Forecast Period

Oral drug delivery has found to be the most preferred and convenient route of drug administration, due to high patient compliance, cost-effectiveness, least sterility constraints, flexibility in the design of dosage form, and ease of production. In oral administration, drugs should be protected under unstable biological environments, including drug degradation induced by the GI tract and first-pass liver effects after oral administration before reaching the targeted sites. The oral drug delivery is majorly driven by the increasing incidence of chronic diseases, reformulation and repositioning of drugs using advanced oral delivery systems, and huge investments made by big pharmaceutical companies on in-house capabilities for the development of oral drug delivery technologies. According to Globocan, 2018 there were a total of 2,129,118 incident cancers in the United States for the year 2018.

North America Novel Drug Delivery Systems (NDDS) - Market - IMG2

North America Novel Drug Delivery Systems (NDDS) Industry Overview

The market players are focusing on the development of innovative treatment options in order to grab maximum market share. Some of the market players are Abbott Laboratories, AstraZeneca PLC, Bayer AG, F. Hoffmann-La Roche AG, GlaxoSmithKline PLC, Johnson & Johnson, Merck & Co., Inc., Novartis AG, Pfizer Inc., and Sanofi SA

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support
Product Code: 60492

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Need of Controlled Release of Drugs
    • 4.2.2 Technological Advancements Promoting Development of NDDS
  • 4.3 Market Restraints
    • 4.3.1 Stringent Regulatory Guidelines and Product Recalls
    • 4.3.2 Stability Issues of the Devices
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Route of Administration
    • 5.1.1 Oral Drug Delivery Systems
    • 5.1.2 Injectable Drug Delivery Systems
    • 5.1.3 Pulmonary Drug Delivery Systems
    • 5.1.4 Transdermal Drug Delivery Systems
    • 5.1.5 Others
  • 5.2 By Mode of NDDS
    • 5.2.1 Targeted Drug Delivery Systems
    • 5.2.2 Controlled Drug Delivery Systems
    • 5.2.3 Modulated Drug Delivery Systems
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Abbott Laboratories
    • 6.1.2 AstraZeneca PLC
    • 6.1.3 Bayer Healthcare Pharmaceuticals
    • 6.1.4 GlaxoSmithKline PLC
    • 6.1.5 Johnson & Johnson
    • 6.1.6 Novartis AG
    • 6.1.7 Merck & Co.
    • 6.1.8 Sanofi SA
    • 6.1.9 Roche Holding AG
    • 6.1.10 Pfizer Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!